Search research articles
Contact Us
Filters
Showing results (211-220 of 235) with videos related to
Page
of 24
Sort By:
American Journal of Clinical Oncology
|
December 18, 1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer
G A Bjarnason, C Cripps, R Goel, et al.
British Journal of Cancer
|
February 16, 2013
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
M Quintela-Fandino, M Krzyzanowska, G Duncan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2014
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M Aglietta, C Barone, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2003
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
M J Moore, J Hamm, J Dancey, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
September 8, 2016
Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3
M M Vickers, C Lee, D Tu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
D J Renouf, P A Tang, D Hedley, et al.
British Journal of Cancer
|
July 30, 2014
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T Golan, Z S Kanji, R Epelbaum, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2015
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
S Y Brulé, D J Jonker, C S Karapetis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
I F Tannock, D Osoba, M R Stockler, et al.
Integrative Organismal Biology (Oxford, England)
|
December 11, 2023
Shaped by Their Environment: Variation in Blue Whale Morphology across Three Productive Coastal Ecosystems
D R Barlow, K C Bierlich, W K Oestreich, et al.
Page
of 24
Search research articles
Search
Showing results (211-220 of 235) with videos related to
Sort By:
Page
of 24
American Journal of Clinical Oncology
|
December 18, 1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer
G A Bjarnason, C Cripps, R Goel, et al.
British Journal of Cancer
|
February 16, 2013
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours
M Quintela-Fandino, M Krzyzanowska, G Duncan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2014
A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer
M Aglietta, C Barone, M B Sawyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 30, 2003
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group
M J Moore, J Hamm, J Dancey, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]
|
September 8, 2016
Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3
M M Vickers, C Lee, D Tu, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2014
A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer
D J Renouf, P A Tang, D Hedley, et al.
British Journal of Cancer
|
July 30, 2014
Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers
T Golan, Z S Kanji, R Epelbaum, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 17, 2015
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17
S Y Brulé, D J Jonker, C S Karapetis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 1996
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
I F Tannock, D Osoba, M R Stockler, et al.
Integrative Organismal Biology (Oxford, England)
|
December 11, 2023
Shaped by Their Environment: Variation in Blue Whale Morphology across Three Productive Coastal Ecosystems
D R Barlow, K C Bierlich, W K Oestreich, et al.
Page
of 24